Foundayo vs Wegovy Pill: Which Is Cheaper and What Differs (2026)

Foundayo and the Wegovy pill both cost $149 a month at the starting dose. After that, the Wegovy pill costs $199 at 4 mg and $299 at 9 or 25 mg, while Foundayo stays at $149 at 2.5 mg and $199 at 5.5 mg through December 31, 2026.

We checked both makers' prices on October 16, 2026.

July 16, 202620 min read

By GLP-1 Picks, an independent comparison publication. Sources linked below. Our editorial policy.

Summarize this article with

Editorial still-life illustrating Foundayo and Wegovy pill comparison for weight loss

Both branded pills start at $149 for the medicine, but dose and provider fees change the bill. The full price ladder for each is in the next section.

Telehealth programs add their own fees: see which services prescribe the Wegovy pill and which prescribe Foundayo, with each program's month-one total.

A prescription is required.

What the trials found: OASIS 4 reported 13.6% mean weight loss with oral semaglutide 25 mg at 64 weeks. ATTAIN-1 reported 11.2% with the highest orforglipron trial dose at 72 weeks.

These primary results come from separate studies, not a randomized comparison between the pills.

How you take them: you take the Wegovy pill in the morning on an empty stomach with up to 4 ounces of water, then wait at least 30 minutes before food, drink or other oral medicines (manufacturer dosing guide).

Foundayo can be taken with or without food.

The short answer:

Pick Foundayo if you want a pill you can take at any time, with or without food.

Pick the Wegovy pill if you want semaglutide, can keep to the empty-stomach morning routine, or have heart disease, since it carries a cardiovascular risk-reduction indication.

At the starting dose both cost $149 a month, so compare the price at the dose you will actually take.

See what each one costs and how to get it

Each page lists who prescribes it and what you pay. Your prescriber decides which one suits you.

Explore Foundayo access and costs →

Which is cheaper, Foundayo or the Wegovy pill?

At the starting dose, neither pill is cheaper: both cost $149 a month for the medicine. The gap opens at the next steps.

Through December 31, 2026, Foundayo's second and third steps cost $149 at 2.5 mg and $199 at 5.5 mg, while the Wegovy pill's cost $199 at 4 mg and $299 at 9 mg.

At the top, the Wegovy pill's 25 mg costs $299; Foundayo's 14.5 and 17.2 mg cost $299 only when you refill within 45 days, otherwise $349.

The milligrams do not match across the two molecules, so compare the step your prescriber puts you on, not the dose number.

We read NovoCare's Wegovy terms and Lilly's Foundayo terms on October 16, 2026.

Which is cheaper, Foundayo or the Wegovy pill?
Price stepFoundayo (orforglipron)Wegovy pill (semaglutide)
Starting dose$149 at 0.8 mg$149 at 1.5 mg
Second step$149 at 2.5 mg through December 31, 2026, then $199$199 at 4 mg
Third step$199 at 5.5 mg through December 31, 2026, then $299$299 at 9 mg
Fourth step$299 at 9 mg$299 at 25 mg, the top dose
Top doses$299 at 14.5 or 17.2 mg with a refill within 45 days, otherwise $349No dose above 25 mg
List price (WAC)$649 a month$1,349.02 a package
Commercial insurance that covers it, with the savings cardAs little as $25 a month, up to $100 off a month, through December 31, 2026As little as $25 a month, up to $100 off a month
Medicare GLP-1 Bridge, outside Part D$50 a month if eligible and authorized$50 a month if eligible and authorized
Where to fillLillyDirect, retail pharmacies and telehealth programs such as Ro and HersNovoCare Pharmacy, a pharmacy with the savings offer, and telehealth programs such as Hers and Ro

Program fees change the answer again.

Hers, which has carried an open FDA warning letter since September 2025, and Ro add a membership on top of either medicine, $39 for your first month and then $149 a month on Hers and on Ro's monthly plan, so a $149 medicine costs $188 in month one and $298 at a refill through those programs; see where you can fill the Wegovy pill and which programs prescribe Foundayo.

The clearest fixed difference is the list price, which matters to insurers more than to you at the counter: Foundayo's $649 WAC is less than half of the Wegovy pill's $1,349.02.

If neither branded pill lands in reach, compounded telehealth is the other cash path, and the discount there is tied to how long a plan you commit to rather than to a coupon: BMI MD's promo pricing advertises compounded semaglutide at $119/month on a 12-month plan against a $229/month month-to-month reference.

Compounded medications are not FDA-approved.

A lower list price matters most to insurers and to Medicare, because it leaves more room to negotiate, which could help Foundayo onto more formularies over time.

Novo Nordisk has announced list price cuts of approximately 50% for Wegovy from January 2027, which would narrow that gap.

Where you can fill Foundayo: since April 12, 2026, through LillyDirect, Amazon Pharmacy, GoodRx, Weight Watchers and Ro.

Telehealth program fees can come on top, so confirm the strength, the refill timing and the full monthly total before you pay.

These are US self-pay prices for a US prescription. Canada, Italy, India and other countries set their own prices, so a figure from abroad will not match.

TrumpRx.gov lists both pills at the same $149 starting price as Lilly and Novo Nordisk; see TrumpRx, LillyDirect and NovoCare prices by dose.

Compare the current product-specific medication and program fees in the Foundayo access guide and Wegovy pill cost guide.

Ask for the amount due now, the prescribed-dose refill price and any care or commitment charges; a starting price is not a multi-month quote.

What is the difference between Foundayo and the Wegovy pill?

The most important difference between Foundayo and the Wegovy pill is that they are not the same type of drug. Both activate the GLP-1 receptor, but they are built differently, and that changes how you take each pill.

Oral Wegovy (semaglutide 25 mg) is a peptide, a modified version of the GLP-1 hormone your gut naturally produces after eating.

Peptides are chains of amino acids, and they are hard to deliver as a pill because stomach acid and digestive enzymes break them apart before they can be absorbed.

Novo Nordisk solved this with a permeation enhancer called SNAC (salcaprozate sodium), which protects the semaglutide molecule and helps it cross the stomach lining into the bloodstream.

The trade-off is a strict routine: you take the pill first thing in the morning on an empty stomach with no more than 4 ounces of plain water, then wait 30 minutes before eating, drinking, or taking any other medications.

Foundayo (orforglipron) is a non-peptide small molecule, an entirely synthetic compound that is not based on the natural GLP-1 hormone at all.

Instead, it was designed from scratch to bind to and activate the same GLP-1 receptor that semaglutide targets.

Because it is a small molecule rather than a fragile peptide chain, it absorbs readily through the gut without being destroyed by stomach acid.

So there is no fasting, no water limit and no wait: you can take it at any time of day, with or without food.

What is the difference between Foundayo and the Wegovy pill?
Foundayo (orforglipron)Oral Wegovy (semaglutide)
ManufacturerEli LillyNovo Nordisk
Drug classNon-peptide small molecule GLP-1 agonistPeptide GLP-1 agonist with SNAC enhancer
FDA approval dateApril 1, 2026December 2025
Approved indicationWeight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidityWeight management in adults with obesity or overweight with comorbidity; cardiovascular risk reduction
Dosing frequencyOnce dailyOnce daily
Food restrictionsNone, take any time, with or without foodMust take on empty stomach, wait 30 min before eating
Water restrictionsNoneNo more than 4 oz plain water
Maximum dose17.2 mg25 mg
Approval pathwayNational Priority Voucher (50-day review)Standard FDA review

That chemistry is why the two pills feel so different day to day.

Semaglutide's peptide structure is what forces the fasting routine, which is hard if your schedule is irregular, you take other medicines in the morning or you want your coffee before 30 minutes are up.

Orforglipron's small-molecule design has no such routine.

Why this matters for you:

If you have ever taken Rybelsus (oral semaglutide for diabetes), you know the fasting routine. Oral Wegovy uses the same SNAC technology and the same restrictions apply.

Foundayo has no such routine; you take it like any other daily tablet. For many people, that difference may decide it.

Approved in the EU:

The European Commission approved oral semaglutide 25mg (Wegovy pill) for weight management in adults on July 15, 2026, following a positive EMA CHMP opinion in May 2026.

Foundayo (orforglipron) has not received European marketing authorization.

How do you take each pill, and how does the dose go up?

Both pills start at a low dose and step up over time, which keeps stomach side effects down. The two schedules differ in how many steps they have and what each day looks like.

Foundayo dosing schedule:

How do you take each pill, and how does the dose go up?
PeriodFoundayo DoseNotes
First step0.8 mg dailyStarting dose; take for at least 30 days
After ≥30 days at 0.8 mg2.5 mg dailyIncrease only if prescribed
After ≥30 days at 2.5 mg5.5 mg dailyIncrease only if prescribed
After ≥30 days at 5.5 mg9 mg dailyIncrease only if prescribed
After ≥30 days at 9 mg14.5 mg dailyOptional prescriber-directed increase
After ≥30 days at 14.5 mg17.2 mg dailyMaximum labeled strength; optional

Oral Wegovy dosing schedule:

How do you take each pill, and how does the dose go up?
PeriodOral Wegovy DoseNotes
Days 1-301.5 mg dailyStarting dose
Days 31-604 mg dailyFirst escalation
Days 61-909 mg dailySecond escalation
Day 91+25 mg dailyMaintenance dose

Foundayo has six labeled dose levels, with at least 30 days at each strength before any increase. Your prescriber may keep you on a dose longer or stop stepping up, depending on how you respond. You should not move up on your own.

Oral Wegovy uses a separate four-step schedule to reach its 25 mg maintenance strength.

Here is what each pill asks of you every day:

  • •Foundayo: Its label does not require Wegovy's empty-stomach morning routine. That does not mean there are no drug interactions or other restrictions. Follow the prescribed instructions and have your pharmacist check your other medicines.
  • •Oral Wegovy: Wake up. Take the pill on a completely empty stomach with a small sip of water (4 oz maximum, plain water only). Swallow the tablet whole. Do not chew, crush or split it. Set a timer for 30 minutes. Do not eat, drink anything else, or take any other oral medications during that waiting period. After 30 minutes, resume your normal routine.

For some people, the Wegovy routine is a minor inconvenience they barely notice.

For others, particularly those with demanding morning schedules, shift workers, people who take multiple morning medications, or those who need coffee first thing, it is a real daily burden.

Clinical data on oral semaglutide (from the Rybelsus program) shows that adherence to fasting requirements meaningfully affects absorption and therefore efficacy.

Patients who do not follow the fasting protocol closely may not absorb the full dose, reducing effectiveness.

Convenience advantage, Foundayo:

Not having a fasting requirement may make Foundayo's routine easier for some people. That is a practical distinction, not proof of better long-term adherence or effectiveness.

Ask how the prescribed schedule fits your meals and other medicines.

What did the separate weight-loss trials find?

ATTAIN-1 evaluated orforglipron over 72 weeks. OASIS 4 assessed the 25 mg semaglutide tablet at 64 weeks.

The table shows each study's primary result. No trial has put people on Foundayo and the Wegovy pill side by side.

What did the separate weight-loss trials find?
Study detailOrforglipron: ATTAIN-1Oral semaglutide: OASIS 4
Studied high dose36 mg trial capsule; not a commercial-tablet instruction25 mg daily tablet
Primary assessment72 weeks64 weeks
Mean body-weight change-11.2%-13.6%
Placebo change-2.1%-2.2%

Higher on-treatment estimates, including 12.4% and 16.6%, describe different analyses. They should not be mixed with the primary estimates or presented as proof of a statistically significant difference between these medicines.

Different follow-up durations and populations further limit a simple comparison.

When you talk to your prescriber, the more useful question is which pill you can take correctly and get reliably. The trial-capsule strengths are not Foundayo tablet dosing instructions.

Follow the current commercial label and your prescriber's plan.

What are the side effects of Foundayo and the Wegovy pill?

Separate studies do not establish which pill you will tolerate better. Keep each safety result with its own formulation, population and placebo group; do not read differences between trials as a direct comparison.

OASIS 4 randomized 307 adults without diabetes: 205 to oral semaglutide 25 mg and 102 to placebo.

The publication describes a 71-week trial, with the weight-loss endpoints assessed at week 64.

Its safety findings and the Wegovy tablet label's adverse-reaction report, section 6.1 are shown separately below.

What are the side effects of Foundayo and the Wegovy pill?
Safety measure and sourceOral semaglutide 25 mgIts placebo group
Participants with gastrointestinal adverse events (OASIS 4 publication)74.0%42.2%
Permanent treatment discontinuation due to adverse reactions (Wegovy tablet label, section 6.1)6.9%5.9%

Gastrointestinal events and stopping treatment are different outcomes. These figures do not establish a safety ranking against Foundayo, and injection-table percentages should not be relabelled as oral Wegovy results.

Foundayo's own prescribing information describes its adverse reactions and warnings.

Boxed warning: Both medicines carry a thyroid C-cell tumor warning and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.

Foundayo's label explains that orforglipron was not active in rats and mice and did not produce tumors in those animals; its warning concerns findings with other GLP-1 agents. Human relevance remains uncertain.

Read the Foundayo prescribing information and Wegovy prescribing information for each product's full warnings.

Symptoms and dose changes

Severe or persistent symptoms need clinical assessment. Follow your own medicine's warning instructions and contact your care team; do not change or overlap treatment on your own.

The side effects guide separates trial rates from warning signs.

Which pill should you choose?

Neither pill is better for everyone. Start with what matters most to you:

Choose Foundayo if:

  • •Convenience is your top priority: Foundayo's no-restrictions dosing (any time, with or without food) eliminates the daily friction that comes with oral Wegovy's fasting requirements. If you know you will struggle with the 30-minute fasting window, Foundayo removes that barrier entirely.
  • •You are a shift worker or have an irregular schedule: the ability to take Foundayo at any time of day, regardless of meals, makes it far more practical for people who do not have a consistent morning routine.
  • •Your prescribed-dose Foundayo quote is lower: compare the actual medication, refill conditions and care fees. A lower list price alone does not establish a lower uninsured checkout total.
  • •You prefer the Eli Lilly ecosystem: if you are already using LillyDirect or have Lilly savings cards, Foundayo fits into the same Lilly pharmacy and savings program.
  • •You want to switch from injectable Zepbound without changing manufacturers: Foundayo gives Lilly patients an oral option within the same portfolio, with clinical data (ATTAIN-MAINTAIN) supporting the switch from injectables.
  • •Your clinician considers Foundayo suitable: discuss realistic goals, tolerability and follow-up rather than selecting a pill for a promised percentage of weight loss.

Choose oral Wegovy if:

  • •You want to discuss the semaglutide evidence: oral Wegovy has its own obesity trial and labeled indications. The larger average in a separate study does not guarantee more weight loss than Foundayo for you.
  • •You have established cardiovascular disease and either obesity or overweight: discuss the Wegovy tablet's labelled cardiovascular indication with your prescriber. General risk factors alone do not establish that indication, and coverage still depends on your plan.
  • •You can reliably follow the morning routine: the tablet requires an empty stomach and at least 30 minutes before food, drink or other oral medicines. Check the schedule with your pharmacist if you take other morning medicines.
  • •You want the most clinically established GLP-1 molecule: semaglutide has years of real-world data, multiple large-scale trials (STEP, OASIS, SELECT), and a track record that orforglipron simply has not had time to build yet.
  • •Your insurance covers Wegovy but not Foundayo: formulary placement will evolve, but oral Wegovy had a head start. Check your plan's current formulary before deciding.
  • •You are on Medicare and eligible for the GLP-1 Bridge: both oral Wegovy and Foundayo are confirmed eligible under the Medicare GLP-1 Bridge program at $50/month live as of July 1, 2026. At parity pricing, the choice between them on Medicare comes down to the same factors as cash-pay: fasting tolerance and efficacy priority.

Not sure which factors matter most for your situation?

Our match quiz accounts for your schedule, insurance, budget, and medication preferences to recommend the best GLP-1 option, including both oral and injectable formulations.

How do the pills compare with Wegovy and Zepbound injections?

Should you switch from a weekly injection to one of these pills? It depends on your results so far and what you want from treatment.

How do the pills compare with Wegovy and Zepbound injections?
Foundayo (pill)Oral Wegovy (pill)Wegovy 2.4 mg (injection)Zepbound (injection)
Mean weight loss, primary analysis11.2% at week 72 (ATTAIN-1, 36 mg trial dose)13.6% at week 64 (OASIS 4, 25 mg)~15% (STEP 1)~18-21% (SURMOUNT-1)
DosingDaily pill, no restrictionsDaily pill, fasting requiredWeekly injectionWeekly injection
Needle-freeYesYesNoNo
Manufacturer self-pay price$149 to $349/mo, by dose and refill timing$149 to $299/mo, by dose$349/mo at 2.4 mg through NovoCare; $199 each for up to two eligible 28-day 0.25 or 0.5 mg home-delivery fills. For the $199 NovoCare delivery offer, you must not have filled a Wegovy injection prescription through NovoCare or NovoCare Legacy before. The prescription must be written and received by December 31, 2026, and shipped by January 31, 2027. The offer covers at most two 28-day fills at 0.25 or 0.5 mg; subsequent fills use the standard dose-specific price. Eligibility and prescription requirements apply.$299 to $449/mo through LillyDirect with a refill within 45 days at 7.5 mg and above; $499 to $699 otherwise
CV indicationNoYesYesNo
MechanismGLP-1 (non-peptide)GLP-1 (peptide)GLP-1 (peptide)GIP/GLP-1 dual (peptide)

The figures in this table come from different studies and do not establish a winner between delivery routes.

If your current treatment is effective, tolerated and affordable, discuss any reason for a change with your prescriber rather than selecting the largest percentage from separate trials.

A move from an injection to a pill, or from one molecule to another, is a prescribing decision.

The specific switching evidence and labelled pathways below have different populations and products; they are not a general plan to step treatment up or down.

Does either pill protect your heart?

Wegovy tablets' current label includes reducing major cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, alongside a reduced-calorie diet and increased physical activity.

Risk factors alone do not establish that indication.

The Foundayo label lists weight management, not a cardiovascular risk-reduction indication.

Improvements in a study's risk markers are not the same as an approved cardiovascular indication.

The labelled indication is relevant to a prescribing and coverage discussion; it does not guarantee that your plan will pay for either pill. Ask about the exact product, indication and applicable plan rules.

Oral Wegovy has published prediabetes data.

In a post hoc analysis of OASIS 4, 71.1% of oral Wegovy participants who had prediabetes at the start had normal blood glucose at week 64, against 33.3% on placebo.

Foundayo is not approved to treat diabetes.

In April 2026 Lilly said it planned to submit orforglipron to the FDA for type 2 diabetes by the end of the second quarter of 2026.

Can you switch to one of these pills from another GLP-1?

People considering a switch may be moving between formulations of one molecule or between different medicines. The cited studies do not directly compare Foundayo with the 25 mg Wegovy weight-management pill.

ACHIEVE-3 instead studied adults with type 2 diabetes and oral semaglutide 14 mg, so it does not settle that obesity-pill choice.

Switching from injectable GLP-1 to Foundayo: Eli Lilly specifically studied this scenario.

The ATTAIN-MAINTAIN trial showed that patients who switched from injectable incretins (including Wegovy) to orforglipron maintained all but 0.9 kg of their previously achieved weight loss on average, according to Lilly's topline results; people who switched from Zepbound kept all but 5.0 kg.

If you want to move from a shot to a pill, that result is worth raising with your prescriber.

Switching from injectable Wegovy to oral Wegovy: The Wegovy label, section 2.5, has a specific pathway between the 2.4 mg weekly injection and 25 mg daily tablet.

It does not require every established injection patient to restart the tablet's 1.5 mg initiation dose.

Your prescriber must decide which labelled pathway fits your current treatment and coordinate the change; do not convert doses yourself.

Switching between Foundayo and oral Wegovy: These are different molecules, not milligram-for-milligram substitutes. Ask your prescriber for a product-specific transition plan and instructions for the new medicine.

Do not use a trial strength, another patient's schedule or a manufacturer match to plan a switch.

Important:

Never switch GLP-1 medications without your prescriber's guidance. Foundayo and oral Wegovy are different molecules with different pharmacokinetics, and there is no established conversion protocol between them.

Your provider needs to manage any transition based on your individual response, current dose, and treatment goals.

What does Foundayo's "73.6% greater weight loss" claim mean?

ACHIEVE-3 compared an orforglipron 36 mg trial capsule with oral semaglutide 14 mg in 1,698 adults with type 2 diabetes over 52 weeks.

It did not test the 25 mg Wegovy weight-management tablet.

The FDA formulation review maps the trial capsule to the commercial 17.2 mg tablet; those strengths are formulation context, not patient dosing instructions.

What does Foundayo's "73.6% greater weight loss" claim mean?
ACHIEVE-3 weight outcome at week 52 (adults with type 2 diabetes)Orforglipron 36 mg trial capsuleOral semaglutide 14 mg
Treatment-regimen analysis8.2% weight reduction5.3% weight reduction
Efficacy analysis9.2% weight reduction5.3% weight reduction

The 73.6% headline describes the relative difference between the rounded efficacy-analysis figures: 9.2% versus 5.3%. The absolute difference is 3.9 percentage points. It does not mean participants lost 73.6% of their body weight.

The treatment-regimen analysis answers a different question and reported 8.2% versus 5.3%.

Keep the population, comparator strength and analysis with the claim.

ACHIEVE-3 does not establish which obesity-approved pill produces more weight loss in adults without diabetes, and a trial mean is not a forecast of your own result.

How fast is each pill selling?

IQVIA counted Foundayo's prescriptions for its first three weeks. After that, the numbers you see are mostly analyst estimates.

Here is what was counted (Week 1 per BioSpace, Week 2 per pharmaphorum) versus what is an estimate:

How fast is each pill selling?
DrugWeek 1 RxWeek 2 RxWeek 3 RxW1→W2 growthW2→W3 growth
Foundayo (oral, April 2026)1,3903,7075,612+167%+51%
Wegovy pill (oral, January 2026)3,07118,410N/A+499%N/A
Zepbound (injectable, Nov 2023)1,100N/AN/AN/AN/A
Wegovy (injectable, June 2021)768N/AN/AN/AN/A

Week 1: Foundayo recorded 1,390 prescriptions over a 2-day capture window (shipped Thursday April 9, weekly cutoff Saturday April 11).

Oral Wegovy hit 3,071 in its launch week with 5 days of capture (launched Monday January 5).

Normalized for capture days, the two pills entered the market at broadly comparable velocity, both substantially outpacing the GLP-1 injectables that came before them (injected Zepbound 1,100 launch-week Rx; injected Wegovy 768).

Week 2: with both pills having a full 7-day window for the first time, oral Wegovy hit 18,410 prescriptions while Foundayo hit 3,707. Oral Wegovy outpaced Foundayo by roughly 5x in their respective Week 2 windows.

The earlier read that Foundayo was "pacing ahead" of Wegovy pill's trajectory turned out to be premature, Wegovy pill's Week 2 surge from 3,071 to 18,410 (a 6.0x multiplier) far outran Foundayo's 1,390 to 3,707 (a 2.7x multiplier).

Week 3: Foundayo reached 5,612 prescriptions, a +51% week-over-week gain, down from the +167% surge seen in Week 2.

This deceleration is a normal launch pattern: an early-adopter surge in Week 2, followed by a step-down in velocity as the first wave clears.

The relevant industry benchmark is IQVIA's 90,000-Rx-by-Week-12 threshold, the level typically cited as a marker of a successful drug launch.

At 5,612 total Rx through Week 3, Foundayo needs to sustain roughly 7,600 additional Rx per week on average over the next nine weeks to reach that benchmark.

Distribution was still ramping: Amazon Pharmacy same-day delivery launched mid-April, and Weight Watchers' formal Foundayo program integration was announced in late April, both channels were not fully active during the first three weeks.

Weeks 4 and later, read these as estimates, not facts:

After Week 3, the weekly Foundayo numbers come only from competing Wall Street reads of IQVIA's "best-estimate" data, and the banks disagree.

Citi pegged the week ending May 22, 2026 at roughly 16,000 total weekly scripts; Jefferies pegged the same stretch (its "Week 7" read) at roughly 11,700.

We do not publish week-by-week figures after Week 3 because nobody has counted them; precise numbers past Week 3 are projections.

What both banks agree on: Foundayo is still running well behind the oral Wegovy pill (~146,000 scripts the same week, per Citi), roughly a 9-to-1 gap at this stage of the two launches.

Lilly's first filed Foundayo revenue number, from its second-quarter 2026 results:

Lilly's second-quarter 2026 results, filed with the SEC on August 5, 2026 (8-K accession 0000059478-26-000077), put a reported figure where the weekly estimates were.

Foundayo booked $98 million in Q2 2026, its first quarter with any reported revenue.

In the same table over the same three months, Mounjaro booked $9.94 billion and Zepbound $4.93 billion, so $14.87 billion of injectable tirzepatide against $98 million of oral orforglipron.

That is roughly 152 to 1, and Foundayo is under half a percent of Lilly's $22.97 billion quarter.

Lilly did add Foundayo to its defined Key Products list this quarter and filed its U.S. submission for orforglipron in type 2 diabetes, so the company is resourcing it as a franchise.

Read the ratio as a starting line rather than a verdict: Q2 was Foundayo's first full quarter on sale.

Why the script count understates real Foundayo demand:

Citi's own caveat is that IQVIA undercounts telehealth referrals, and telehealth is about 35% of where Foundayo is actually dispensed (versus ~20% retail and ~45% LillyDirect, per the Week-3 channel split Lilly gave analysts, with roughly 20,000 patients on the drug by early launch).

So part of the gap with the Wegovy pill comes from *where* people fill Foundayo, which the count misses.

The benchmark to watch is RBC Capital Markets' marker that a successful launch reaches ~90,000 weekly prescriptions by Week 12; Foundayo entered June well short of that pace.

Why the Week 2 gap widened:

Two reasons stand out.

(1) More places to get it: oral Wegovy ships through both NovoCare direct and the March 18, 2026 Hims/Hers × Novo Nordisk partnership. Hers lists the pill medication from $149, plus required membership at $39 in month one and $149/mo ongoing, making that path $188 initially and $298/mo thereafter.

Foundayo is available through LillyDirect and multiple telehealth partners including Ro, Sesame Care, Shed, Found, and Hers, which has carried an open FDA warning letter since September 2025.

(2) A known name: people have known Wegovy for years through the injection, and Foundayo is new.

What this means for you: the Wegovy pill sells far more and you can get it in more places. Sales volume does not tell you which pill fits you; your morning routine, your prescriber's view and your price at your dose do.

Frequently Asked Questions

Is Foundayo the same as Wegovy in pill form?

No. Foundayo (orforglipron) and oral Wegovy (semaglutide) are completely different molecules made by different companies.

They both activate GLP-1 receptors, but orforglipron is a synthetic small molecule while semaglutide is a modified peptide hormone.

Can I take Foundayo with food?

Yes. Foundayo can be taken at any time of day, with or without food, and with any beverage. There are no fasting requirements or water restrictions.

This is one of its primary advantages over oral Wegovy, which must be taken on an empty stomach.

Which pill causes fewer side effects?

The cited separate studies do not establish which pill is safer or easier for you to tolerate.

Review the Foundayo label and Wegovy label for your medicine's risks.

A percentage from one trial should not be used to rank it against a different formulation or study.

Will my insurance cover Foundayo?

It depends on your plan, not only on your pharmacy benefit manager.

CVS Caremark removed its new-to-market block on Foundayo from June 1, 2026, "where approved for coverage by plans," and added Zepbound back to its commercial formularies as an additional preferred option from October 1, 2026 (CVS Caremark, May 28, 2026, checked October 15, 2026).

Employers and other plan sponsors still decide what their members get, and Express Scripts and OptumRx set their own formularies, so check your plan's current list.

If your plan covers Foundayo, Lilly's savings card can bring eligible commercially insured patients to as low as $25/month. Without coverage, LillyDirect self-pay starts at $149/month at 0.8 mg.

On Medicare, the GLP-1 Bridge has covered Foundayo at $50 a month since July 1, 2026 if you qualify.

Can I switch from oral Wegovy to Foundayo?

Only with a prescriber's product-specific plan. Foundayo and oral Wegovy are different molecules, and their milligram strengths are not interchangeable.

Discuss the current medicine, timing, tolerability and instructions for the new prescription rather than assuming a starter dose or direct conversion.

Is Foundayo approved for diabetes?

Not yet. Foundayo is currently FDA-approved only for chronic weight management. Eli Lilly has announced plans to submit orforglipron for a Type 2 diabetes indication in 2026, but that approval has not yet occurred.

If you need a GLP-1 for diabetes, your current options include Ozempic, Rybelsus, Mounjaro, and others, see our beginner's guide for the full list.

Where to go next

How we checked: this comparison draws on FDA prescribing information, published data from the ATTAIN-1 trial (Foundayo), OASIS 4 trial (oral Wegovy), the Foundayo FDA approval record, the oral Wegovy launch announcement, and the EMA Wegovy product authorization.

We checked NovoCare's Wegovy terms and Lilly's Foundayo terms on October 16, 2026. For an overview of all oral GLP-1 pills, see our oral GLP-1 pills compared guide.

If you are new to GLP-1 treatment, start with our ranked list of telehealth providers to find a platform that lists the medication you are discussing.

The match quiz organizes budget, insurance and service preferences. For either pill's actual medication and care charges, use the product-specific access guides linked above and confirm the written quote.

Medical disclaimer:

This article is for informational purposes only and does not constitute medical advice. Foundayo and oral Wegovy are prescription medications with significant side effects and contraindications.

Do not start, stop, or switch medications without consulting your physician or healthcare provider. Individual results vary, and the clinical trial data cited here represents population averages, not guaranteed outcomes.

We checked the manufacturer prices on October 16, 2026; they can change.

Affiliate disclosure: Some links in this article are affiliate links. If you join a program through one, we may earn a commission at no extra cost to you.

Medicare & GLP-1

Medicare GLP-1 Coverage Guide

On Medicare? From July 1, 2026, the Medicare GLP-1 Bridge sets a $50 monthly copay for Wegovy, Zepbound and Foundayo. Our guide explains who qualifies and what it covers.

Read the Medicare guide →
Independent Clinical Perspective

What the doctors say

Quotes from named doctors and medical bodies, each linked to where they said it. We did not ask for them, and they do not endorse any provider.

“It's not just filling out a form online and then having some random healthcare provider sign off on it. There are concerns with some of these online programs that there's not a proper evaluation, there's not a baseline, and there's not proper supervision.”
Marc-Andre Cornier, MD, endocrinologist; immediate past president of The Obesity Society
Medical University of South Carolina
On why some online/telehealth GLP-1 programs fall short of a proper clinical standard of care.
“Compounded drugs can be important for overcoming shortages or meeting unique patient needs, but compounders should not try to compound drugs in a way that circumvents FDA's approval process.”
Marty Makary, MD, MPH, FDA Commissioner
U.S. Food and Drug Administration
Announcing 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products.
FDA.gov ↗ · Mar 2026
“We do not recommend the use of these alternatives. If you use these compounded alternatives, you may not be getting what you hoped for. You may also get something you did not want (other active substances have been found in some compounded versions).”
Obesity Medicine Association, Joint statement with The Obesity Society & Obesity Action Coalition
OMA / TOS / OAC
Joint patient-facing statement on compounded GLP-1 alternatives not reviewed by the FDA.

Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.